TimesSquare Capital Management LLC Makes New $22.04 Million Investment in Mirum Pharmaceuticals, Inc. $MIRM

TimesSquare Capital Management LLC acquired a new position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 300,649 shares of the company’s stock, valued at approximately $22,041,000. TimesSquare Capital Management LLC owned approximately 0.59% of Mirum Pharmaceuticals at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of the business. MCF Advisors LLC increased its stake in shares of Mirum Pharmaceuticals by 76.4% during the third quarter. MCF Advisors LLC now owns 427 shares of the company’s stock valued at $31,000 after purchasing an additional 185 shares in the last quarter. CWM LLC increased its stake in Mirum Pharmaceuticals by 30.8% during the 3rd quarter. CWM LLC now owns 683 shares of the company’s stock valued at $50,000 after purchasing an additional 161 shares in the last quarter. Comerica Bank raised its holdings in Mirum Pharmaceuticals by 45.1% in the first quarter. Comerica Bank now owns 895 shares of the company’s stock worth $40,000 after buying an additional 278 shares during the last quarter. Jones Financial Companies Lllp lifted its stake in shares of Mirum Pharmaceuticals by 34.0% in the third quarter. Jones Financial Companies Lllp now owns 957 shares of the company’s stock worth $70,000 after buying an additional 243 shares in the last quarter. Finally, Osaic Holdings Inc. grew its holdings in shares of Mirum Pharmaceuticals by 46.5% during the second quarter. Osaic Holdings Inc. now owns 1,106 shares of the company’s stock valued at $56,000 after buying an additional 351 shares during the last quarter.

Mirum Pharmaceuticals Stock Up 1.1%

Mirum Pharmaceuticals stock opened at $103.10 on Monday. Mirum Pharmaceuticals, Inc. has a one year low of $36.88 and a one year high of $105.74. The stock has a fifty day moving average of $86.38 and a 200 day moving average of $76.10. The company has a debt-to-equity ratio of 1.06, a quick ratio of 3.16 and a current ratio of 3.31. The stock has a market cap of $5.30 billion, a PE ratio of -119.88 and a beta of 0.49.

Analyst Ratings Changes

A number of equities analysts recently weighed in on MIRM shares. Citigroup restated an “outperform” rating on shares of Mirum Pharmaceuticals in a report on Friday, December 19th. Stifel Nicolaus boosted their price target on Mirum Pharmaceuticals from $92.00 to $98.00 and gave the stock a “buy” rating in a research note on Tuesday, December 16th. JMP Securities set a $95.00 price objective on Mirum Pharmaceuticals in a research report on Wednesday, November 5th. Wall Street Zen upgraded Mirum Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday, January 17th. Finally, Raymond James Financial restated a “strong-buy” rating and set a $110.00 target price on shares of Mirum Pharmaceuticals in a research note on Thursday, December 11th. One analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $107.25.

Insider Transactions at Mirum Pharmaceuticals

In other Mirum Pharmaceuticals news, Director Patrick J. Heron acquired 131,425 shares of the business’s stock in a transaction dated Friday, January 23rd. The stock was purchased at an average price of $68.48 per share, with a total value of $8,999,984.00. Following the transaction, the director directly owned 459,010 shares in the company, valued at approximately $31,433,004.80. The trade was a 40.12% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Joanne Quan sold 6,911 shares of the company’s stock in a transaction on Tuesday, January 20th. The stock was sold at an average price of $90.27, for a total value of $623,855.97. Following the completion of the sale, the insider owned 11,305 shares of the company’s stock, valued at $1,020,502.35. This trade represents a 37.94% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 45,136 shares of company stock worth $4,352,029. 22.87% of the stock is currently owned by corporate insiders.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.